Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A. Fisher, K Turner, James Scriven et al.|UCL Discovery (University College London)|2022Cited by 58
Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trialBenjamin A. Fisher, Pamela Kearns, Tonny Veenith et al.|medRxiv|2021Cited by 7
Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised multicentre open adaptive multi-arm multi-stage trialCatalyst investigators, Pamela Kearns, Benjamin A. Fisher et al.|Unknown|2021Cited by 0